The Effect of Dalfampridine in Hereditary Spastic Paraparezi: Randomized Controlled Trial

• Status: Not yet recruiting
• Trial end date: 2023-01-30
• Target enrollment: 0
• Participant gender: All

Summary

Hereditary spastic paraplegias (HSPs) are characteterised by progressive lower extremity spasticity and weakness. The signs and symptoms of HSP are consequences of retrograde degeneration of the longest nerve fibres in the corticospinal tracts and posterior columns. There is a clinically and genetically heterogenity with more than 70 identified causative genes. HSP can be inherited as autosomal dominant , autosomal recessive, X-linked or maternal (mitochondrial) trait. To date, there are no effective treatments that can slow or halt the progressive disability or reverse the neurodegeneration in HFS. Treatment is symptomatic and includes physical therapy, oral antispastic drugs, botulinum toxin therapy, and intratechal baclofen pump implantation.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: European University of Lefke
• Treatments: 4-Aminopyridine

Criteria

Inclusion Criteria:Patients will be included if they are diagnosed as HSP -

Exclusion Criteria:Patients will be excluded if they had exposure to Botilinium toxin, renal injury, a history of seizures or any change in the treatment of spasticity within the last 6 months.

-